Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 48

  • 1 276 clinical trials
  • 446 recruiting
  • 379 conditions
  • 28 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer327Asthma88Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV57COVID-1939Pulmonary arterial hypertension38Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Pneumonia32Small cell lung cancer32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza28Interstitial lung disease28Lung neoplasm malignant28Cystic fibrosis24Conjunctivitis allergic23Pulmonary hypertension23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 276 clinical trials

Gastroenteropancreatic neuroendocrine tumour disease+5

Not yet recruiting

Study on the Safety and Effectiveness of Domvanalimab and Zimberelimab for Adults with Advanced Rare Cancers Resistant to Standard Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab
  • Sponsor:Hospices Civils De Lyon

Pneumonia bacterial+1

Not yet recruiting

Study on Preventing Early Respiratory Infections in Intubated Patients Using Ceftriaxone, a Cough Simulator, and Subglottic Secretion Aspiration

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ceftriaxone
  • Sponsor:Hospital Clinico San Carlos

Bronchitis

Not yet recruiting

Study on the Effectiveness of Elixirium Thymi Compositum for Treating Acute Bronchitis in Children

Registered drug
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:LIQUID EXTRACT OF THYME (1:3.45-3.85), EXTRACTION SOLVENT: ETHANOL 27%(V/V)
  • Sponsor:Semmelweis University

Eosinophilic granulomatosis with polyangiitis

Not yet recruiting

Study on the Effectiveness of Tezepelumab for Adults with Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Imperial College London Limited

Abdominal infection+5

Not yet recruiting

Study on Aztreonam, Avibactam, and Metronidazole for Treating Infections in Neonates and Infants Under 9 Months with Gram-Negative Bacterial Infections

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Avibactam Sodium
  • Sponsor:Pfizer Inc.

Non-small cell lung cancer

Not yet recruiting

Study of Cabozantinib for Patients with Non-Small Cell Lung Cancer and MET Deregulation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Fondazione Ricerca Traslazionale

Non-small cell lung cancer stage I

Not yet recruiting

Study on Datopotamab Deruxtecan and Rilvegostomig for Stage I Non-Small Cell Lung Cancer Patients with ctDNA-Positive or High-Risk Features

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Acute respiratory distress syndrome

Not yet recruiting

Study on Premedication with Ketamine or Fentanyl for Patients with Respiratory Distress Syndrome Receiving Surfactant Treatment

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Fentanyl Citrate
  • Sponsor:Pohjois-Pohjanmaan hyvinvointialue

Acute respiratory distress syndrome

Not yet recruiting

Study on Pirfenidone for Preventing Lung Fibrosis in Patients with Acute Respiratory Distress Syndrome (ARDS)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pirfenidone
  • Sponsor:Ospedale San Raffaele S.r.l.

Non-small cell lung cancer stage IIIA+1

Not yet recruiting

Study on Pembrolizumab as Maintenance Therapy for Patients with Unresectable Stage III Non-Small Cell Lung Cancer After Chemo-Radiotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Universita' Degli Studi Di Torino

Non-small cell lung cancer

Not yet recruiting

Study on the Best Treatment Sequence for Advanced Non-Small Cell Lung Cancer with EGFR Mutations Using Dacomitinib and Osimertinib

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dacomitinib
  • Sponsor:Fondazione Ricerca Traslazionale

Renal cell carcinoma+2

Not yet recruiting

Study on the Safety and Effectiveness of AL8326 for Patients with Small Cell Lung Cancer Needing Second-Line Treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Al8326
  • Sponsor:Advenchen Pharmaceuticals LLC

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin169 clinical trialsPembrolizumab145 clinical trialsCisplatin128 clinical trialsPemetrexed108 clinical trialsPaclitaxel80 clinical trialsDurvalumab71 clinical trialsAtezolizumab50 clinical trialsNivolumab49 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.